ReviewJournal of blood medicine2016
Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia.
Review in Journal of blood medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Romiplostim in Combination With Low-dose Rituximab and High-dose Dexamethasone as Frontline Treatment for Immune Thrombocytopenia
Single Arm Evaluation of Romiplostim to Prevent Chemotherapy Induced Thrombocytopenia in Patients With Ewing Sarcoma
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis.British journal of haematology · 2020Pooled it
- Pharmacokinetics, Safety, and Pharmacodynamics of Romiplostim in Chinese Subjects With Immune Thrombocytopenia: A Phase I/II Trial.Clinical pharmacology in drug development · 2022Trial
- From Platelet Toxicity to Precision Targeting: Evolving Strategies to Overcome Thrombocytopenia in BCL-2/BCL-XL Inhibition.Health science reports · 2026Article
- Platelet Disorders and Medication Strategies.Thrombosis and haemostasis · 2026Review
- Peptide and Protein Tags for the Half-Life Extension of Therapeutic Agents: A Review Article.The protein journal · 2026Review
- Thromboembolic adverse events associated with TPO-RA in ITP treatment: a pharmacovigilance analysis of the FDA Adverse Event Reporting System.Frontiers in immunology · 2026Article
- Review
- Systemic Lupus Erythematosus with Refractory Immune Thrombocytopenia Progressing to Catastrophic Anti-Phospholipid Syndrome During Thrombopoietin Receptor Agonist Therapy: A Case Report.Journal of clinical medicine · 2025Article
- Thrombopoietic agents enhance bone healing in mice, rats, and pigs.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2024Article
- Thrombopoietin Receptor Agonists: Can These Be the Future Answer to the Deadly Thrombocytopenia in Dengue Fever?Cureus · 2019Review
- Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia.Therapeutic advances in hematology · 2019Review
- The thrombopoietin mimetic romiplostim leads to the complete rescue of mice exposed to lethal ionizing radiation.Scientific reports · 2018Article
- Eltrombopag in immune thrombocytopenia: efficacy review and update on drug safety.Therapeutic advances in drug safety · 2018Review
- Transitioning patients with immune thrombocytopenia to second-line therapy: Challenges and best practices.American journal of hematology · 2018Review
- Romiplostim for treatment of thrombocytopenia in dogs: A retrospective assessment and clinical outcomes.Journal of veterinary internal medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inhibition of platelet production and mediated by antiplatelet antibodies is a well-known mechanism causing low platelet counts in immune thrombocytopenia (ITP). Use of thrombopoietin receptor agonists increases platelet counts and decreases the risk of bleeding in patients with ITP. Two such thrombopoietin receptor agonists, romiplostim and eltrombopag, are approved by the US Food and Drug Administration to treat thrombocytopenia in adults, and most recently, children with persistent or chronic ITP. This review focuses on the efficacy data and safety analysis of the pooled data from the clinical trials evaluating romiplostim for treatment of adults with ITP. The rates of hemorrhage, thrombosis, hematologic and nonhematologic cancers, and myelodysplastic syndrome were not overrepresented among the groups who received romiplostim versus placebo or other standard-of-care treatments. Yet, as after-market experience with thrombopoietin receptor agonists increases, there are emerging reports of increased incidence of thrombosis and bone marrow reticulin among patients who are treated with long-term use of these agents. Ongoing clinical research will continue to evaluate romiplostim's efficacy and safety in other primary and secondary thrombocytopenic states.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.